progression-free survival
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Hui Wu, Wenzhi Shu, Yongfeng Ding, Qiong Li, Ning Li, Qiyue Wang, Yinqi Chen, Yuejun Han, Dongdong Huang, Haiping Jiang
BMC Cancer 25(1) 1369
BACKGROUND: Anti-programmed cell death-1 (PD-1) immunotherapy and platinum-based chemotherapy are key components of first-line treatment for advanced Gastric or Gastroesophageal Junction (G/GEJ) cancer. However, the role of immune cells infiltrating the tumor microenvironment (TME) in predicting both therapy responses is still unclear. METHODS: ORIENT-16 is a randomized, double-blind, placebo-controlled, phase 3 clinical trial, and enrolled 650 patients with unresectable locally advanced or metastatic G/GEJ cancer between January 3, 2019, and August 5, 2020. For patients enrolled from the First Affiliated Hospital of Zhejiang University School of Medicine, we analyzed progression-free survival(PFS) and overall survival (OS) based on PD-L1 expression and landmark analysis, and developed a multiplexed immunofluorescence (mIF) assay for CD4, CD8, PD-L1, CD68 and FoxP3 coupled with digital image analysis and machine learning to assess prognostic survival associations of immune cells. RESULTS: A total of 54 eligible patients were enrolled in this study, 35 received sintilimab plus platinum-based chemotherapy and 19 received placebo plus platinum-based chemotherapy. For patients with PD-L1 combined positive score (CPS) < 10, survival disparities between anti-PD-1 immunotherapy and chemotherapy emerged 300 days post-treatment. High PD-L1 expression correlated with longer survival in anti-PD-1 therapy but less benefit in platinum-based chemotherapy. The mIF analysis also demonstrated significantly higher stromal PD-L1 density in immunotherapy responders, but tended to be lower in chemotherapy responders. Besides, high tumor stromal CD8 expression could be used as a positive biomarker in anti-PD-1 immunotherapy, and high tumor stromal CD4 expression was found associated with worse prognosis in platinum-based chemotherapy. CONCLUSIONS: Increased PD-L1 expression was associated with an increased effect on anti-PD-1 immunotherapy and reduced benefit from chemotherapy. The signature of TME immune cells has the potential to predict the response of anti-PD-1 immunotherapy and chemotherapy in G/GEJ cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03745170.
3 个 Figure · 11 个 KM 面板
Fig. 2 Kaplan-Meier plot of progression-free survival and overall survival. Progression-free survival in patients with PD-L1 CPS ≥ 10 ( A ) and PD-L1 CPS < 10 ( C ); overall survival in patients with PD-L1 CPS ≥ 10 ( B ) and PD-L1 CPS < 10 ( D ); ✴Small lesions (longest diameter < 10 mm or pathological lymph node short diameter ≥ 10 mm to < 15 mm) were taken as unmeasurable lesions. HR, hazard ratio
Fig. 2 · Panel A
Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel B
Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel C
Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 · Panel D
Panel D 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 Survival curves using the LANDMARK method of overall survival
Fig. 3 · Panel Overall_Survival_Landmark_Method
Panel Overall_Survival_Landmark_Method 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 Progression-free survival and overall survival subgroup analysis according to PD-L1 CPS. Progression-free survival in all randomized patients ( A ) and in patients receiving immunotherapy plus chemotherapy ( C ) and placebo plus chemotherapy ( E ). Overall survival in all randomized patients ( B ) and in patients receiving immunotherapy plus chemotherapy ( D ) and placebo plus chemotherapy ( F ). CI, confidence interval; CPS, combined positive score; HR, hazard ratio
Fig. 4 · Panel A
Panel A 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel B
Panel B 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel C
Panel C 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel D
Panel D 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel E
Panel E 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4 · Panel F
Panel F 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。